Long-acting parenteral drug delivery systems for the treatment of chronic diseases

Adv Drug Deliv Rev. 2023 Jul:198:114862. doi: 10.1016/j.addr.2023.114862. Epub 2023 May 7.

Abstract

The management of chronic conditions often requires patients to take daily medication for an extended duration. However, the need for daily dosing can lead to nonadherence to the therapy, which can result in the recurrence of the disease. Long-acting parenteral drug delivery systems have the potential to improve the treatment of chronic conditions. These systems use various technologies, such as oil-based injectables, PLGA-based microspheres, and in situ forming gel-based depots, to deliver different types of drugs. The use of long-acting parenteral formulations for the treatment of chronic infections such as HIV/AIDS and tuberculosis is a recent development in the field. Researchers are also exploring the use of long-acting parenteral formulations for the treatment of malaria, with the aim of reducing dosing frequency and improving adherence to treatment. This review discusses various aspects of long-acting formulation development, including the impact of the physicochemical properties of the drug, the type of long-acting formulation, and the route of administration. The clinical significance of long-acting formulations and recent advances in the field, such as long-acting nanoformulations and long-acting products currently in clinical trials, have also been highlighted.

Keywords: Aqueous suspension; Extended-release; Intramuscular; Microspheres; Pharmacokinetics; Sustained release.

Publication types

  • Review

MeSH terms

  • Chronic Disease
  • Delayed-Action Preparations
  • Drug Delivery Systems*
  • Humans

Substances

  • Delayed-Action Preparations